- Emerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO 2L / 3L patients
- In 16 patients JANX007 displayed:
- High PSA response rates: 100% achieved best PSA50 declines
- Deep PSA declines: 63% achieved best PSA90 declines; 31% achieved best PSA99 declines
- Durable PSA response at ≥ 12 weeks: 75% maintained PSA50 declines; 50% maintained PSA90 declines
- Encouraging anti-tumor activity: 50% ORR (4/8) and 63% DCR (5/8)
- Well-tolerated safety profile: CRS and TRAEs primarily limited to cycle 1 and grades 1 and 2; Maximum tolerable dose has not yet been reached
- Janux to host virtual investor event today at 4:30 PM Eastern Time
Janux Announced Updated Interim Clinical Data For JANX007 Clinical Program
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.